Abstract
Description
China is expected to become the fifth largest drug market in the world by 2010
with a growth rate of 20-25 percent per annum in next three years. As China
joins the World Trade Organization (WTO) and integrates more completely into
the global economy, it will further open the door to a lucrative drug market
for overseas pharmaceutical companies, which attracts more and more overseas
pharmaceutical manufacturers and producers to enter such drug market and seize
a larger part of such drug market. However, the Chinese social environment for
the protection of intellectual property right is complex. The locally produced
generics and copy products dominate the Chinese drug market. It is estimated
that about 97 percent of the drugs produced by local companies are generics or
counterfeits.
Facing such complex social environment and market, most overseas and
multinational pharmaceutical companies fear that their imported drugs and
pharmaceuticals produced in China will be imitated or copied, in turn, their
intellectual property will be infringed and benefit will be violated. What
reason incurred such fear of overseas and multinational pharmaceutical
companies? Why did Eli Lilly & Company fail in its litigation of patent
infringement dispute case in China? Why can Pfizer win in an administrative
proceeding against the Patent Reexamination Board of the China State
Intellectual Property Office (SIPO) for its Viagra patent? Lack of knowledge
of the Chinese intellectual property right system and legislation institution,
the cultural difference between China and Western countries as well as the
language barriers incurred such result.
China' s Guidebook for Pharmaceutical Patent Protection is an essential
resource for overseas and multinational pharmaceutical companies to achieve a
successful patent protection for their intellectual property in China. This
guidebook, targeting overseas and multinational pharmaceutical companies and
combining case studies of patent infringement dispute in China from them, will
provide a comprehensive and thorough knowledge of the Chinese patent system
and legislation institution to guide overseas and multinational pharmaceutical
companies step by step to achieve a successful patent protection for their
intellectual property in China, which is beginning from the organization
structure and the responsibility of Chinese patent authorities, the
application for patent, the examination and approval of application for
patent, the protection of patent right, to design for compositions of
optimized patent protection strategies. Its audiences are the executives from
overseas and multinational pharmaceutical companies who have the preliminary
knowledge of patent. It is also a textbook for the readers studying in the
patent protection for intellectual property rights relating to
pharmaceuticals. After having skimmed through this guidebook, audiences and
readers can not only be clearly aware of the Chinese patent system and
legislation institution, but also design an optimized patent protection
strategy for themselves to acquire an adequate protection for their patent
right in China.
Guidebook Highlights
China' s Guidebook for Pharmaceutical Patent Protection provides a
comprehensive and thorough knowledge of the Chinese patent system relating to
pharmaceuticals, the detailed administrative, civil and criminal judicial
pathways for protections of patent right, and the design for composition of
optimized protection strategies.
- The organization structure of patent authorities and judicial system;
- A comprehensive and thorough knowledge of the Chinese patent system and
the relevant laws and administrative regulations relating to pharmaceuticals;
- The patentable subject matter relating to pharmaceuticals in China;
- Administrative protection for patent right;
- Civil judicial procedures and remedies for patent right;
- Criminal punitions for infringement of patent right;
- Design for compositions of optimized protection strategies;
- Case studies and comparative analyses of patent infringement disputes.
Company' s Description
Access China Management Consulting Ltd. is a professional provider of
managements and consulting services specifically designed to provide overseas
clients a virtual gateway to enter the lucrative market of China. Access China
is headquartered in Nanjing, Jiangsu Province, Eastern China.
At present, company provides consulting services for foreign clients as follows.
- Research of Chinese pharmaceutical industry and market;
- pharmaceutical patent applications; license transfer; registration of
imported drugs and new drugs; management of laws and regulations on
pharmaceuticals;
- Consultancy on the Chinese laws, administrative regulations on
pharmaceutical administration;
- Provide analyses of feasibility for mergers and acquisitions of the
existing Chinese pharmaceutical enterprises;
- Act as agent, within a range of authorized, implement operation to
purchase and merge the existing Chinese pharmaceutical enterprises in
accordance with the order of foreign investors;
- Help foreign investors make the registration of Foreign Investment
Access China Management Consulting pursues the principle of “integrating
resources and creating value” to contribute to foreign clients.
| 
View Cart
